Remedy N1 System Used in FIH Fully Remote Neurointerventional Procedures

October 8, 2025—Remedy Robotics, Inc., announced the first-in-human (FIH) procedures with its remotely operable endovascular robotic system, Remedy N1.

According to Remedy Robotics, the Remedy N1 system combines the company’s hardware with artificial intelligence (AI)–enabled software to deliver fast, safe, and effective intervention to patients with cardiovascular conditions, including stroke, heart attack, or vascular trauma, whether the patient is across the room or across the globe. The Remedy N1 system includes an endovascular robot that integrates with any catheterization lab and AI-enabled software.

The series of FIH procedures with the Remedy N1 system were recently led by Vitor Mendes Pereira, MD, a neurosurgeon at St. Michael’s Hospital and Professor at the University of Toronto in Toronto, Canada.

The company reported that the procedures were fully remote operations conducted at two sites within the Unity Health Toronto network—St. Michael’s Hospital and St. Joseph’s Health Centre.

The procedures demonstrated the potential of the Remedy N1 system to deliver lifesaving treatments for cardiovascular emergencies such as stroke, regardless of distance, stated the company.

“Performing minimally invasive cardiovascular interventions with this level of robotic assistance, and entirely remotely, is absolutely transformative, even for experts in the field,” commented Dr. Pereira in the company’s press release. “The Remedy N1 system delivers exceptional maneuverability, dexterity, and visual clarity, enabling precise control and a significantly enhanced patient experience. The success of these world-first in-human remote procedures is a strong validation of the platform’s precision, safety, and potential to transform patient care globally.”

The successful completion of the procedures marks a new phase of expanded clinical trials and the development of additional applications across a range of cardiovascular surgical specialties for the Remedy N1 system, which remains under development and is not yet available for sale, advised the company.